These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34801033)

  • 1. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression.
    Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B
    Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Changes in Myofibroblasts Affect the Carcinogenesis and Prognosis of Bladder Cancer Associated With Tumor Microenvironment Remodeling.
    Du Y; Sui Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
    Front Cell Dev Biol; 2022; 10():833578. PubMed ID: 35309916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Du Y; Liu Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
    Front Immunol; 2023; 14():1113756. PubMed ID: 37153545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
    Wang T; Ding G; Wang X; Cui Y; Ma X; Ma J; Wu J
    Arch Med Res; 2024 Jan; 55(1):102927. PubMed ID: 38154234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
    Zhang H; Song J; Dong J; Liu Z; Lin L; Wang B; Ma Q; Ma L
    Front Genet; 2021; 12():551605. PubMed ID: 33732281
    [No Abstract]   [Full Text] [Related]  

  • 6. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
    Liu Y; Wu Y; Zhang P; Xu C; Liu Z; He C; Liu Y; Kang Z
    Front Oncol; 2021; 11():636870. PubMed ID: 33747959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
    Du Y; Wang B; Jiang X; Cao J; Yu J; Wang Y; Wang X; Liu H
    Front Oncol; 2021; 11():620674. PubMed ID: 33747932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.
    Du Y; Miao W; Jiang X; Cao J; Wang B; Wang Y; Yu J; Wang X; Liu H
    Front Oncol; 2021; 11():683951. PubMed ID: 34150647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 11. CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database.
    Wang J; Xie Y; Qin D; Zhong S; Hu X
    Front Oncol; 2022; 12():1031706. PubMed ID: 36419891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer.
    Wang Y; Wang J; Zeng T; Qi J
    Cancer Genet; 2024 Nov; 288-289():43-53. PubMed ID: 39260052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer.
    Peng Z; Ye M; Ding H; Feng Z; Hu K
    J Transl Med; 2022 Jul; 20(1):302. PubMed ID: 35794563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
    Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
    Front Oncol; 2022; 12():724261. PubMed ID: 35237505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
    Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
    Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.